VIEW MORE
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for...
VHIO’s Director Josep Tabernero selected as a candidate for the AACR Board of Directors (2023-2026): voting now open
VIEW MORE
Presented by VHIO’s Director Josep Tabernero during this week’s annual ASCO Gastrointestinal Cancers Symposium, January 19-21, results from the phase...
On the ground at ASCO GI Cancers Symposium: results from SUNLIGHT study point to practice-changing care for patients with refractory metastatic colorectal cancer
VIEW MORE
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with...
NAPOLI-3: NALIRIFOX shows promise as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma

Latest News

The VHIO Radiomics Group participates in this new European project On January 1, 2023, a new EU-funded research project establishing...

New Research Project ODELIA launches to revolutionise Artificial Intelligence in Healthcare using Swarm Learning
The VHIO Radiomics Group participates in this new European project On January 1, 2023, a new EU-funded research project establishing...

We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for...

VHIO’s Director Josep Tabernero selected as a candidate for the AACR Board of Directors (2023-2026): voting now open
We are delighted to announce that our Director Josep Tabernero is among the selected candidates for the American Association for...

Presented by VHIO’s Director Josep Tabernero during this week’s annual ASCO Gastrointestinal Cancers Symposium, January 19-21, results from the phase...

On the ground at ASCO GI Cancers Symposium: results from SUNLIGHT study point to practice-changing care for patients with refractory metastatic colorectal cancer
Presented by VHIO’s Director Josep Tabernero during this week’s annual ASCO Gastrointestinal Cancers Symposium, January 19-21, results from the phase...

Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with...

NAPOLI-3: NALIRIFOX shows promise as first-line therapy in patients with metastatic pancreatic ductal adenocarcinoma
Metastatic Pancreatic Ductal Andenocarcinoma (mPDAC) is an aggressive type of cancer that is most frequently detected at advanced stages with...

Research Programs

PRECLINICAL & TRANSLATIONAL RESEARCH
Cellular Plasticity and Cancer Group

Our group focuses on the interplay between cellular plasticity, stem cells and cancer. Cellular plasticity is recognized today as a critical feature of cancer cells that enables them to transit between different cellular states, including reversible transitions.

Cellular Plasticity and Cancer Group
PRECLINICAL & TRANSLATIONAL RESEARCH
Growth Factors Group

We focus our research on mechanisms of resistance to targeted therapies and most importantly, how to overcome it by showing that breast cancers resistant to T-DM1, an antibody-drug conjugate ADC)- can be efficiently treated with the second generation ADC SYD985 (Nadal-Serrano et al.).

Growth Factors Group
CORE TECHNOLOGIES
Cancer Genomics Group

VHIO’s Cancer Genomics Group serves as a Core Technology laboratory. We are also dedicated to translational research as well as the development of novel genomic tests.

Cancer Genomics Group

PRINCIPAL RESEARCHERS

JUDIT_BALMAÑA
Judith Balmaña
Hereditary Cancer Genetics Group

We focus on the clinical development of PARP inhibitors (PARPi) in early gBRCA1/2 breast cancer, and novel combinations in the…

Cristina-Saura00007
Cristina Saura
Breast Cancer & Melanoma Group

The main area of expertise of the Breast Cancer Group is clinical research focused on drug development and associated translational…

Alena Gros
Alena Gros
Tumor Immunology and Immunotherapy Group

Our group focuses on better understanding the naturally occurring T-cell response to cancer and establishing ways to exploit these antitumor…

César_Serrano
César Serrano
Sarcoma Translational Research Group

Our group focuses on the study of sarcomas with oncogenic dependency on specific drivers of disease. Among these, gastrointestinal stromal…

Events

Friday 10 February 23 - 12:00 PM scientific-seminars Seminars Itay Tirosh | Dissecting intra-tumor heterogeneity by single cell RNA-seq
Thursday 16 February 23 - 11:00 AM Patients Cancer, menopause and sexuality. Myths and realities
Friday 24 February 23 - 12:00 PM scientific-seminars Seminars Chiara Ambrogio | Targeting KRAS: Pre-Clinical Validation & Therapeutic Perspectives to Overcome Drug Resistance
Thursday 9 March 23 - 11:00 AM Patients Legal doubts. What are the rights of breast cancer patients?